Education
About Us
Working with TipRanks
Follow Us
biote (BTMD)
NASDAQ:BTMD
BTMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.04 - $7.95
Previous CloseN/A
Volume19.10K
Average Volume (3M)109.61K
Market Cap
$174.24M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)7.1
Beta1.06
Next Earnings
Aug 06, 2025EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding33,073,277
10 Day Avg. Volume97,155
30 Day Avg. Volume109,615
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.54Price Target Upside27.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Business GrowthThe supplements business experienced a 25% growth due to a strategic move to Amazon.
Consumer LoyaltyThe market opportunity remains attractive, and the end consumer remains loyal to BTMD's products even in a challenging economic environment.
Management StrategyManagement announced an organizational restructuring to support new clinic growth by increasing sales representatives by 25% without increasing headcount.
Bears Say
Clinic GrowthNew clinic growth began to soften as BTMD implemented the proprietary clinical decision support software.
Revenue DeclineAverage selling price declined modestly, negatively affecting Procedure revenue.
Software TransitionOngoing software transition issues are expected to linger, impacting trends for more than two quarters.
biote News
BTMD FAQ
What was biote’s price range in the past 12 months?
biote lowest stock price was $3.04 and its highest was $7.95 in the past 12 months.
What is biote’s market cap?
biote’s market cap is $174.24M.
When is biote’s upcoming earnings report date?
biote’s upcoming earnings report date is Aug 06, 2025 which is in 5 days.
How were biote’s earnings last quarter?
biote released its earnings results on May 07, 2025. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.078 by $0.292.
Is biote overvalued?
According to Wall Street analysts biote’s price is currently Undervalued.
Does biote pay dividends?
biote does not currently pay dividends.
What is biote’s EPS estimate?
biote’s EPS estimate is 0.08.
How many shares outstanding does biote have?
biote has 33,073,277 shares outstanding.
What happened to biote’s price movement after its last earnings report?
biote reported an EPS of $0.37 in its last earnings report, beating expectations of $0.078. Following the earnings report the stock price went up 11.976%.
Which hedge fund is a major shareholder of biote?
Currently, no hedge funds are holding shares in BTMD
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.54 (27.65% Upside)
$5.54 (27.65% Upside)
Blogger Sentiment
Bullish
BTMD Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.21%
12-Months-Change
Fundamentals
Return on Equity
-7.92%
Trailing 12-Months
Asset Growth
-22.94%
Trailing 12-Months
Company Description
biote
Biote (BTMD) is a leading company in the field of bioidentical hormone replacement therapy, primarily focusing on empowering practitioners with training, support, and products to help optimize hormone levels in patients. Operating within the healthcare sector, Biote provides a comprehensive ecosystem that includes training programs, certification, and a wide range of hormone replacement products designed to enhance patient well-being and vitality.
BTMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were notable achievements such as revenue growth, improved profit margins, and strong performance in the dietary supplements segment, these were offset by challenges, including a decrease in procedure revenue, reduced adjusted EBITDA, and increased SG&A expenses. The company is undergoing a strategic realignment aimed at driving growth, but the impacts of these changes may take time to materialize.Read More>BTMD Stock 12 Month Forecast
Average Price Target
$5.54
▲(27.65%Upside)
Technical Analysis
Oncology Institute
―
COMPASS Pathways
―
DocGo
―
Airsculpt Technologies
―
Auna S.A. Class A
―
Ownership Overview
43.76% Insiders
10.33% Mutual Funds
25.76% Other Institutional Investors
11.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---